Form 4: TENAX THERAPEUTICS Director Michael Davidson Reports Significant Option Grant and Warrant Holdings

TENAX THERAPEUTICS Director Michael H. Davidson filed a Form 4, disclosing the acquisition of 80,000 stock options and detailing existing holdings of common stock, pre-funded warrants, and additional stock options.

Summary

• Michael H. Davidson, a Director of TENAX THERAPEUTICS, INC. (TENX), filed a Form 4 statement of changes in beneficial ownership.
• The filing reports the acquisition of 80,000 stock options with an exercise price of $5.75, exercisable from July 1, 2026, and expiring on July 1, 2035.
• Davidson beneficially owns 2,881 shares of common stock directly.
• Existing derivative holdings include a pre-funded warrant for 47,500 shares at an exercise price of $0.01, issued on August 8, 2024, with no expiration date.
• Also held is a warrant for 25,000 shares at an exercise price of $4.50, issued on August 8, 2024, expiring on the earlier of 30 trading days following the Phase 3 LEVEL Study topline data announcement, proportionally upon exercise of the pre-funded warrant if prior to the topline data announcement, or August 8, 2029.
• Additional stock options include 4 shares at $3,200 (exercisable June 10, 2022, expiring June 10, 2031), 4 shares at $992 (exercisable June 9, 2023, expiring June 9, 2032), and 100,000 shares at $5.94 (exercisable December 10, 2025, expiring December 10, 2034).

Sentiment

Score: 5

Explanation: The document is a factual report of insider beneficial ownership and transactions, primarily detailing the acquisition of new stock options and existing derivative holdings, without providing performance or outlook statements that would indicate positive or negative sentiment.

Positives

• The acquisition of 80,000 new stock options indicates management's continued alignment with shareholder interests and potential confidence in future performance.
• The pre-funded warrant has a very low exercise price of $0.01, offering significant leverage for the holder.

Negatives

• Some older stock options have very high exercise prices ($3,200 and $992), which may be significantly out-of-the-money depending on the current stock price, potentially indicating past stock splits or reverse splits that adjusted the share count but not the per-share exercise price in the filing.
• The expiration of the 25,000 share warrant is tied to the timing of the Phase 3 LEVEL Study topline data, introducing uncertainty regarding its ultimate value and exercisability timeline.

Risks

• The value and expiration of the 25,000 share warrant are directly linked to the success and timing of the topline data announcement from the company's Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) (NCT05983250), introducing clinical trial risk.

Future Outlook

The expiration terms of the 25,000 share warrant are tied to the initial public announcement of topline data from the company's Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) (NCT05983250), indicating a future milestone for the company.

Industry Context

This filing is typical for a publicly traded biotechnology or pharmaceutical company, where insider holdings often include a mix of common stock, stock options, and warrants, reflecting compensation structures and alignment with clinical development milestones, such as Phase 3 trial results.

Comparison to Industry Standards

• Insider ownership, including stock options and warrants, is a standard component of executive and director compensation in publicly traded companies, particularly in the biotech sector where long-term incentives tied to clinical milestones are common.
• The specific exercise prices and quantities are company-specific, but the instruments themselves are standard for aligning management interests with shareholder value creation.

Stakeholder Impact

• Shareholders: Changes in insider ownership can influence investor confidence and perception of management's alignment with shareholder interests. The exercise of options and warrants could lead to future dilution.

Next Steps

• Topline data announcement from the Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) (NCT05983250).

Key Dates

Keywords

TENAX THERAPEUTICS, TENX, Michael H. Davidson, Form 4, insider transaction, beneficial ownership, stock options, warrants, pre-funded warrant, SEC filing, corporate governance, clinical trial, LEVEL Study, PH-HFpEF